Supplement ArticlesTrends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based studyFerretti, Stefanoa,b; Bossard, Nadinee,f,g,h; Binder-Fouchard, Florencei,j,k; Faivre, Jeanl; Bordoni, Andream; Biavati, Patriziac; Frassoldati, Antoniod Author Information aDepartment of Public Health, Area Vasta Emilia Centrale Cancer Registry, Ferrara Local Health Unit bDepartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara cDepartment of Public Health, Area Vasta Emilia Centrale Cancer Registry, Bologna Local Health Unit, Bologna dClinical Oncology Unit, Department of Specialty Medicine, University Hospital Ferrara, Ferrara, Italy eDepartment of Biostatistics, University Hospital of Lyon fUniversity of Lyon, Lyon gUniversity of Lyon 1 hCNRS, UMR 5558,Biometry and Evolutionary Biology Laboratory (LBBE), BioMaths-Health Department iFrench Network of Cancer Registries (Francim), Toulouse jBas-Rhin Cancer Registry, Department of Epidemiology and Public Health, EA 3430, Faculty of Medicine, University of Strasbourg kDepartment of Public Health, University Hospital of Strasbourg, Strasbourg lRegistre Bourguignon des Cancers Digestifs, CHU de Dijon; INSERM U 866; University of Burgundy, Dijon, France mRegistro Tumori del Canton Ticino, Istituto cantonale di patologia, Locarno, Switzerland *List of the members available at https://links.lww.com/EJCP/A137 Correspondence to Stefano Ferretti, MD, Ferrara Local Health Unit, Area Vasta Emilia Centrale Cancer Registry, University of Ferrara, Ferrara, Italy e-mail: [email protected] European Journal of Cancer Prevention 26():p S56-S62, January 2017. | DOI: 10.1097/CEJ.0000000000000298 Buy SDC Metrics Abstract Liver cancer represents a major clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from liver cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and provide trends in net survival and dynamics of excess mortality rates (EMRs) up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000–2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These trend analyses were carried out using a flexible excess-rate modeling strategy. There were little differences between the six countries in the 5-year age-standardized net survival (2000–2004): it ranged from 13% (France and Portugal) to 16% (Belgium). An increase in the net age-standardized survival was observed in all countries between 1992 and 2004, both at 1 year and at 5 years (the highest in Spain, the lowest in France). Generally, patients aged 60 years showed the highest increase. There was a progressive decrease in EMR over the 5-year- period following diagnosis. The study confirmed the poor prognosis of liver cancer. Innovative treatments might improve the prognosis as well as preventive screening of cirrhotic patients with good liver function. Efforts are also needed to improve registration practices. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.